| General information |
| Database: | DB00817 |
| Objective: | Inflammatory myofibroblastic tumor (IMT) is a distinctive mesenchymal neoplasm characterized by a spindlecell proliferation with an inflammatory infiltrate. Approximately half of IMTs carry rearrangements of the anaplastic lymphoma kinase (ALK) locus on chromosome 2p23, causing aberrant ALK expression |
| Authors: | Butrynski JE, et al |
| Title: | Crizotinib in ALKrearranged inflammatory myofibroblastic tumor. |
| Journal: | N Engl J Med. |
| Year: | 2010 |
| PMID: | 20979472 |
| Trial Design |
| Clinical Trial Id: | NCT00585195 |
| Agent: | crizotinib
|
| Target: | Hepatocyte growth factor receptor, ALK, ROS1
|
| Cancer Type: | Inflammatory myofibroblastic tumor |
| Cancer Subtype: | myofibroblastic tumor |
| Therapy Type: | mono |
| Therapeutic Combination Type: | NA |
| Therapeutic Combination Content: | NA |
| Study Type: | a doseescalationphase I trial |
| Key Patients Feature: | pts with ALKrearranged inflammatory myofibroblastic tumor |
| Biomarker: | ALKrearranged |
| Biomark Analysis: | These results support the dependence of ALKrearranged tumors on ALKmediated signaling and suggest a therapeutic strategy for genomically identified patients with the aggressive form of this softtissue tumor. |
| Control Group Info: | single arm |
| Treatment Info: | £Î£Á |
| Primary End Point: | NA |
| Secondary End Point: | NA |
| Patients Number: | 2 |
| Trial Results |
| DLT_MTD: | NA |
| Objective Response Rate: | £ô£è£å£ù¡¡report a sustained partial response to the ALK inhibitor crizotinib (PF02341066, Pfizer) in a patient with ALKtranslocated IMT, as compared with no observed activity in another patient without the ALK translocation. |
| Disease Control Rate: | NA |
| Median Time to Progression: | NA |
| Median PFS A vs. C: | NA |
| Median OS A vs. C: | NA |
| Adverse Event(agent arm): | NA |
| Conclusions: | These results support the dependence of ALKrearranged tumors on ALKmediated signaling and suggest a therapeutic strategy for genomically identified patients with the aggressive form of this softtissue tumor. |